Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
The Korean Journal of Internal Medicine
;
: 252-255, 2006.
Article
in English
| WPRIM
| ID: wpr-223932
ABSTRACT
Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunction, the combination of these drugs has not been investigated. We report here on a case of successful treatment of a patient suffering with severe liver dysfunction and metastatic gastric cancer; the patient was treated with a combination of capecitabine and oxaliplatin (XELOX). The initial bilirubin level of the patient was 10.9 mg/dL. After two cycles of treatment, his bilirubin level decreased to 2.1 mg/dL. He has experienced an excellent radiological response and he has received six cycles of XELOX chemotherapy. XELOX chemotherapy is feasible and it can be associated with positive outcomes for the patients suffering with metastatic gastric cancer and severe liver dysfunction.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Organoplatinum Compounds
/
Stomach Neoplasms
/
Prodrugs
/
Adenocarcinoma
/
Follow-Up Studies
/
Liver Failure
/
Deoxycytidine
/
Drug Therapy, Combination
/
Fluorouracil
/
Gastrectomy
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
/
Male
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS